Allscripts Healthcare Solutions EPS misses by $0.06, misses on revenue

Allscripts Healthcare Solutions (NASDAQ:MDRX): Q1 Non-GAAP EPS of $0.09 misses by $0.06; GAAP EPS of -$0.13 misses by $0.07.

Revenue of $417M (-3.6% Y/Y) misses by $4.14M.

Press Release

https://seekingalpha.com/news/3571596-allscripts-healthcare-solutions-eps-misses-0_06-misses-on-revenue

La Jolla Pharma makes a run at Tetraphase Pharma

TetraPhase Pharmaceuticals (NASDAQ:TTPH) discloses that it has received an unsolicited bid from La Jolla Pharmaceutical Company (NASDAQ:LJPC) consisting of $22M in cash and an additional $12.5M payable via a contingent value right (CVR). The board is considering the offer.

On March 26, it agreed to be acquired by AcelRx Pharmaceuticals (NASDAQ:ACRX) for ~$14.4M in an all-stock deal.

https://seekingalpha.com/news/3570959-la-jolla-pharma-makes-run-tetraphase-pharma

Teva posts strong Q1, cash flow ops up 172%

Teva Pharmaceutical Industries (NYSE:TEVA) Q1 results:

Revenues: $4,357M (+5.0%).

Generics: $2,433M (+4.6%); Anda: $426M (+12.4%); Copaxone: $319M (-4.8%); Austedo: $122M (+64.9%); Bendeka/Treanda: $105M (-13.9%); Ajovy: $33M (+65.0%).

Net income: $69M (+165.7%); non-GAAP net income: $835M(+27.7%); EPS: $0.06 (+160.0%); non-GAAP EPS: $0.76 (+26.7%).

Cash flow ops: $305M (+172.3%).

Teva Pharmaceutical EPS beats by $0.17, beats on revenue

https://seekingalpha.com/news/3571074-teva-posts-strong-q1-cash-flow-ops-up-172

Moderna cleared for Phase 2 study of COVID-19 vaccine

Alongside Q1 results, Moderna (NASDAQ:MRNA) says the FDA has given the green light to begin the Phase 2 study on its novel coronavirus vaccine (mRNA-1273).

It’s expected to start imminently, with the goal of a Phase 3 study to begin in early summer, and approval as soon as 2021.

https://seekingalpha.com/news/3571075-moderna-cleared-for-phase-2-study-of-covidminus-19-vaccine

Bausch Health hit COVID-19 headwinds in Q1; guidance cut

Bausch Health Companies (NYSE:BHC) Q1 results:

Revenues: $2,012M (-0.2%); product sales: $1,986M (-0.2%).

Bausch + Lomb: $1,114M (-0.4%); Salix: $477M (+7.2%); Ortho Dermatologics: $133M (-3.6%); Diversified Products: $288M (-8.6%).

B + L/International contributed ~55% of revenue, Salix ~24%, Ortho Dermatologics ~7%.

Net loss: ($152M) (-192.3%); non-GAAP net income: $316M (-11.7%); loss/share: ($0.43) (-186.7%).

Non-GAAP EBITDA: $813M (-4.5%).

2020 guidance: Revenue: $7.80B – 8.20B from $8.65B – 8.85B; non-GAAP EBITDA: $3.15B – 3.35B from $3.50B – 3.65B.

Shares down 4% premarket on light volume.

Bausch Health Companies EPS beats by $0.01, misses on revenue

https://seekingalpha.com/news/3571103-bausch-health-hit-covidminus-19-headwinds-in-q1-guidance-cut

Biomerica up on Covid-19 rapid test’s CE mark approval

Biomerica’s (NASDAQ:BMRA) test, which is expected to cost $10, received a CE mark to be sold in countries outside the U.S.

The test is a finger prick blood test, with results on whether someone is positive or negative for Covid-19 antibodies (to determine if someone has had an immune response to exposure) are expected to be returned within 10 minutes.

BMRA will continue to supply its cassette version of its disposable finger prick test to its distribution partners who are supplying multiple customers.

Chembio Diagnostics earlier this week provided an update on its antibody test, which sent shares higher.

https://seekingalpha.com/news/3571136-biomerica-jumps-34-on-covidminus-19-rapid-tests-ce-mark-approval

Bristol-Myers Squibb affirms guidance, sees 20% earnings growth in 2021

Bristol-Myers Squibb (NYSE:BMY) Q1 results:

Revenues: $10,781M (+13.1%) (includes Celgene).

Top sellers: Revlimid: $2,915M (+13.1%); Eliquis: $2,641M (+37.2%); Opdivo: $1,766M (-1.9%); Orencia: $714M (+11.6%).

Growth remains elusive for Opdivo, sales were down 2% in Q4 2019 as well. Growth peaked at 45% in Q3 2018.

Net loss: ($766M) (-145.3%); non-GAAP net income: $3,956M (+119.3%); EPS: ($0.34) (-132.7%); non-GAAP EPS: $1.72 (+56.4%).

2020 guidance: revenues: $40.0B – 42.0B (unch); EPS: $0.37 – 0.57 from $0.75 – 0.95; non-GAAP EPS: $6.00 – 6.20 (unch).

2021 guidance: Non-GAAP EPS: $7.15 – 7.45.

Shares up 2% premarket on light volume.

Bristol-Myers Squibb EPS beats by $0.27, beats on revenue

https://seekingalpha.com/news/3571113-bristol-myers-squibb-affirms-guidance-sees-20-earnings-growth-in-2021